Review finds endocannabinoid system modulation shows promise for treating tobacco addiction
A review of endocannabinoid-based approaches to tobacco use disorder found that CB1 neutral antagonists and FAAH inhibitors showed the most promise for smoking cessation and relapse prevention.
Quick Facts
What This Study Found
CB1 receptor neutral antagonists and fatty acid amide hydrolase (FAAH) inhibitors demonstrated positive effects across multiple addiction-related factors including nicotine reinforcement, cue-induced reinstatement, and withdrawal. The CB1 inverse agonist rimonabant was effective for cessation but caused psychiatric side effects.
Key Numbers
Rimonabant (CB1 inverse agonist) was effective for smoking cessation but withdrawn due to psychiatric adverse effects. CB1 neutral antagonists and FAAH inhibitors showed positive effects across several addiction-related endpoints.
How They Did This
Expert review examining studies on endocannabinoid modulation (CB1 receptor, CB2 receptor, anandamide, and 2-AG pathways) across addiction-related factors: nicotine reinforcement, reinstatement of drug seeking, withdrawal severity, and executive function.
Why This Research Matters
Tobacco use disorder remains a leading cause of preventable death, and existing treatments have high relapse rates. The endocannabinoid system offers novel targets that could complement current cessation strategies.
The Bigger Picture
The failure of rimonabant highlighted the need for endocannabinoid-based drugs that can reduce addiction without the mood-related side effects. Newer approaches targeting FAAH or using neutral CB1 antagonists may thread this needle.
What This Study Doesn't Tell Us
Much of the evidence is from preclinical models; few human clinical trials exist for CB1 neutral antagonists or FAAH inhibitors in tobacco cessation specifically; the field is still at an early stage.
Questions This Raises
- ?Could FAAH inhibitors serve as both cessation aids and relapse prevention agents?
- ?Would combining endocannabinoid modulators with existing treatments improve outcomes?
Trust & Context
- Key Stat:
- CB1 neutral antagonists and FAAH inhibitors showed positive effects across multiple addiction-related measures
- Evidence Grade:
- Expert review with largely preclinical evidence; few human clinical trials in this specific application.
- Study Age:
- Published in 2020.
- Original Title:
- Novel therapeutic and drug development strategies for tobacco use disorder: endocannabinoid modulation.
- Published In:
- Expert opinion on drug discovery, 15(9), 1065-1080 (2020)
- Authors:
- Butler, Kevin(3), Le Foll, Bernard(40)
- Database ID:
- RTHC-02444
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What happened with rimonabant?
Rimonabant was a CB1 receptor inverse agonist that showed effectiveness for smoking cessation but was withdrawn from markets due to serious psychiatric side effects including depression and suicidal ideation. This prompted the search for endocannabinoid modulators without these risks.
How might the endocannabinoid system help with quitting smoking?
The endocannabinoid system is involved in reward processing, stress response, and habit formation, all relevant to tobacco addiction. Modulating this system through CB1 neutral antagonists or FAAH inhibitors may reduce nicotine's rewarding effects and lower relapse risk without the mood side effects of earlier approaches.
Read More on RethinkTHC
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cross-addiction-quit-weed-start-drinking
- is-weed-addictive
- is-weed-addictive-science
- quitting-weed-and-alcohol
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-02444APA
Butler, Kevin; Le Foll, Bernard. (2020). Novel therapeutic and drug development strategies for tobacco use disorder: endocannabinoid modulation.. Expert opinion on drug discovery, 15(9), 1065-1080. https://doi.org/10.1080/17460441.2020.1767581
MLA
Butler, Kevin, et al. "Novel therapeutic and drug development strategies for tobacco use disorder: endocannabinoid modulation.." Expert opinion on drug discovery, 2020. https://doi.org/10.1080/17460441.2020.1767581
RethinkTHC
RethinkTHC Research Database. "Novel therapeutic and drug development strategies for tobacc..." RTHC-02444. Retrieved from https://rethinkthc.com/research/butler-2020-novel-therapeutic-and-drug
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.